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ABSTRACT	 ﾠ
Aberrant activation of signaling by the Wnt pathway is strongly implicated in the onset and 
progression of numerous types of cancer. Owing to the persistent dependence of these tumors on 
Wnt signaling for growth and survival, inhibition of this pathway is considered an attractive 
mechanism-based therapeutic approach. Oncogenic activation of Wnt signaling can ensue from a 
variety of distinct aberrations in the signaling pathway, but most share the common feature of 
causing increased cellular levels of β-catenin by interfering with its constitutive degradation. β-
Catenin serves as a central hub in Wnt signaling by engaging in crucial protein-protein interactions 
with both negative and positive effectors of the pathway. Direct interference with these protein-
protein interactions is a biologically compelling approach toward suppression of β-catenin 
hyperactivity, but such interactions have proven intransigent with respect to small-molecule 
targeting. Hence β-catenin remains an elusive target for translational cancer therapy. Here, we 
report the discovery of a hydrocarbon-stapled peptide that directly targets β-catenin and interferes 
with its ability to serve as a transcriptional co-activator for TCF proteins, the downstream 
transcriptional regulators of the Wnt pathway. 
\body	 ﾠ
The canonical Wnt (Wingless and INT-1) signal transduction cascade regulates the expression of 
numerous genes involved in cell differentiation, proliferation, and survival (1). Wnt is a diffusible 
ligand protein that initiates the Wnt signaling cascade through engagement with a transmembrane 
complex comprising Frizzled and the low density lipoprotein-related receptor (LRP) complex. The 
events that ensue from this engagement are critically dependent upon the protein β-catenin, which 
serves as a hub for transmission of the Wnt signal from the plasma membrane to the nucleus. In the 
absence of Wnt, β-catenin is recruited into a multicomponent “destruction complex” formed inter 
alia by the proteins adenomatous polyposis coli (APC), Axin, casein kinase 1α (CK1α) and 
glycogen synthase kinase 3β (GSK3β) (Fig. 1A). In this destruction complex, β-catenin undergoes 
phosphorylation by CK1α and GSK3β, which is followed by ubiquitination and proteasomal 
degradation of β-catenin (1). This constitutive degradation of β-catenin in the absence of a Wnt 
signal results in low steady-state levels of the protein. Engagement of Wnt with Frizzled/LRP 
causes Axin to translocate to the transmembrane receptor complex, thereby inhibiting the 3 
destruction complex (1). Consequently, β-catenin accumulates in the cell and undergoes 
translocation to the nucleus, where it serves to recruit powerful co-activators (1) such as CBP and 
BCL9 to DNA-bound transcriptional regulators of the TCF/LEF family (Fig. 1A). In addition, β-
catenin acts as structural component of cell-cell adherens junctions, a function that is considered to 
be independent of its involvement in canonical Wnt signaling. In these cell junctions, β-catenin is 
tightly bound to phosphorylated cadherins (2). 
Activated Wnt signaling serves a critical role in many tissue types during embryonic development, 
but ordinarily becomes quiescent post-development in most tissues. In adults, activated Wnt 
signaling continues to serve a role in stem cell maintenance and tissue regeneration, being essential 
e.g. in perpetual regeneration of the intestinal lining. Inappropriate and chronic activation of Wnt 
signaling is strongly implicated in the initiation and progression of several types of cancer (1) but is 
most strikingly manifest in sporadic colorectal cancers, with approximately 90% of all cases being 
associated with high-level constitutive activation of Wnt signaling (3). In most cases, constitutive 
Wnt activation appears to result from a reduced ability of the destruction complex to recruit and 
degrade β-catenin, owing to mutations in components of the complex, especially APC and Axin, 
and in β-catenin itself (3,4). The Wnt pathway is thus one of several embryonic pathways, also 
including Notch and Hedgehog that are co-opted in certain transformed cells to support tumor 
growth and survival (5). Activation of these embryonic pathways is generally associated with 
increased stem cell-like behavior in cancers and thus is linked with a poor prognostic outcome (5). 
Consequently, there exists particular interest in specific inhibitors of these embryonic pathways in 
general, and of the Wnt pathway in particular. 
Published efforts to inhibit Wnt-dependent signaling have for the most part involved phenotypic 
screening of small-molecule libraries (6-14). The most active compounds reported thus far either 
inhibit tankyrase, an Axin stabilizer (IWR-1 and XAV939) (7,8), or activate CK1α (pyrvinium) (9); 
these affect Wnt signaling primarily by stimulating the activity of the β-catenin destruction 
complex. Though these efforts have provided valuable tool compounds, the therapeutic utility of 
tankyrase inhibitors and CK1α activators is likely to be limited by the fact that most disease-causing 
mutations are either in APC or in pathway components downstream of the destruction complex (3). 
Additionally, tankyrase and CK1α are involved in non-Wnt-dependent cellular processes (8,9), 
increasing the risk of undesirable off-pathway effects. Other inhibitors of the Wnt signaling 4 
pathway have been reported to decrease the transcriptional activity of the downstream TCF/LEF 
transcriptional activator complex and to reduce the growth of cultured human colon cancer cells 
(11-14). One of these compounds NC043 has been shown not to interact directly with the 
transactivation complex (11), but rather to act by a yet uncharacterized indirect mechanism. 
Another such compound ICG-001 targets the general coactivator CBP (12) and therefore is unlikely 
to be Wnt pathway-specific. In three cases, molecules have been identified that disrupt the β-
catenin/TCF interaction in vitro (13-15), but the molecular target(s) and therefore the exact 
mechanisms of these inhibitors have not been conclusively identified, rendering difficult the 
optimization of these relatively weak hit compounds. Thus there remains significant impetus for the 
discovery of compounds that directly target key functional interaction sites on β-catenin via a 
rigorously defined molecular mechanism. 
Assessing various options for a design-oriented approach toward inhibition of the β-catenin 
pathway, we opted for several reasons to focus on the interaction between β-catenin and TCF 
transcription factor. Firstly, the β-catenin/TCF interaction is well-established as a key downstream 
nodal point of the Wnt pathway (16-18) and its importance in tumor cell growth maintenance has 
been highlighted by co-expression of dominant negative versions of TCF as well as by the 
sensitizing effect of small interfering RNAs that down regulate TCF protein levels (19). Secondly, 
the nature of the interaction between β-catenin and peptide ligands, including the β-catenin binding 
domains (CBD) of TCF proteins, has been characterized structurally (16-18). In β-catenin/TCF 
structures, the CBD comprises a C-terminal α-helical segment and an extended structure, connected 
by a disordered loop (16,17). These wrap themselves around the midriff of the of the β-catenin 
armadillo repeat domain (Fig. 1B). 
Inhibition of protein-protein interactions (PPIs) by cell-permeable molecules is considered 
particularly challenging, especially when the protein-protein interface is highly extended, as it is 
with β-catenin and TCF; thus it is unsurprising that efforts to identify direct-acting small molecule 
antagonists of the β-catenin/TCF interaction have not met with success. On the other hand, recent 
successes in inhibiting even extended PPIs using the hydrocarbon-stapled α-helix technology (20-
27) suggested the possibility of employing this approach toward β-catenin/TCF antagonism; this 
notion was strengthened by the presence of the requisite α-helical interaction domain in TCF. Helix 5 
stapling entails the introduction of a synthetic all-hydrocarbon brace across one face of an α-helical 
peptide, which in numerous cases has been shown to stabilize the bioactive α-helical conformation, 
to increase binding affinity for the target, to decrease the rate of proteolytic degradation, and most 
importantly, to effect robust cell penetration by endocytic vesicle trafficking (20-29). Importantly, 
stapled peptides have demonstrated robust efficacy in animal models of human disease, including 
T-cell acute lymphoblastic leukemia by direct targeting of the Notch transactivation complex (24) 
and BCL2-driven lymphoma (27). Here we report the combined use of stapled peptide technology 
and directed evolution to identify stapled peptides that directly bind the TCF-docking site on β-
catenin, thereby antagonizing transcriptional activation via the Wnt signaling pathway. We provide 
definitive structural and biochemical evidence for the molecular mechanism of these compounds, 
and we demonstrate that they interfere selectively with Wnt/β-catenin signaling in cells and in a 
pathway-specific manner reduce the viability of Wnt-addicted cancer cells. 
RESULTS	 ﾠ
Stapled	 ﾠα-ﾭ‐helical	 ﾠpeptides	 ﾠtargeting	 ﾠβ-ﾭ‐catenin	 ﾠ
As our goal was to inhibit TCF binding to β-catenin, we first considered the CBD of TCF4 as a 
candidate for production of stapled peptides. The extended portion of this peptide (Fig. 1B) 
represents a potential liability, as such unstructured regions are typically susceptible to proteolytic 
cleavage, hence we first assessed the importance of the extended region for binding to β-catenin. 
Using fluorescence polarization (FP) assays, we found that a fluorescein-labeled peptide comprising 
only the α-helical region of the TCF4 CBD (Fig. 1B) (17) exhibited no detectable interaction with 
β-catenin (Kd > 10 µM, SI Fig. 1B), whereas binding was readily observed with a peptide 
containing both the α-helical and extended regions (Kd = 0.26 µM). Having determined that 
extended region thus appears to be essential for recognition of β-catenin by TCF4 CBD, we sought 
alternative peptide frameworks for production of stapled peptides. We noted that the CBD of Axin 
is comprised exclusively of α-helical structure, and the binding site for the Axin CBD on β-catenin 
overlaps substantially with that of the TCF4 α-helix, though the two helices bind in reverse 
orientation (Fig. 1B). We therefore evaluated Axin-derived peptides for binding to β-catenin, again 
using FP. Though the fluorescein-labeled 15-mer Axin CBD peptide exhibited only moderate 6 
affinity for β-catenin (Kd ~ 5 µM, SI Fig. 1B), this was sufficient to move forward with this 
framework, given the expected affinity boost that typically results from staple incorporation. 
An all-hydrocarbon staple is incorporated into a peptide by introduction of two α-methyl,α-alkenyl 
amino acids (SI Fig. 1C) during chain extension via solid-phase peptide synthesis, followed by 
closure of the macrocyclic bridge using ruthenium-mediated ring-closing olefin metathesis (Fig. 
2A) (30-32). Inspection of the crystal structure of the Axin/β-catenin complex (18) revealed four 
positions in the Axin CBD (Fig. 2B, red) that are not involved in β-catenin binding; these were 
selected as potential staple incorporation sites. From this set of prospective stapling positions, those 
having the preferred relative spacings of i,i+4 and i,i+7 were then selected (31). On the basis of 
these design criteria, stapled Axin (StAx) CBD peptides StAx-1, -2 and -3 (Fig. 2C) were designed. 
Fluorescein-labeled versions of these stapled peptides (fStAx-1, -2, and -3) were synthesized and 
evaluated for α-helicity and binding to β-catenin. As judged by circular dichroism spectra (Fig. 2D), 
the α-helical character of all three stapled peptides increased relative to that of the fluorescein-
labeled wild-type Axin (fAxWT), with StAx-3 showing the greatest α-helicity (51 %). The affinities 
of the first-generation StAx peptides to β-catenin were then determined by FP (Fig. 2E). Whereas 
fStAx-1 and -2 showed no affinity enhancement upon incorporation of the staple, fStAx-3 exhibited 
significantly enhanced affinity for β-catenin (Kd = 60±2 nM) relative to fAxWT. The StAx-3 
sequence was thus selected for further optimization. 
Affinity	 ﾠand	 ﾠcell	 ﾠpermeability	 ﾠoptimization	 ﾠof	 ﾠStAx	 ﾠpeptides	 ﾠ
In a parallel series of experiments, we sought to affinity-optimize the Axin peptide sequence 
through the use of phage display technology (33). We therefore generated a library of phage-
displayed peptides based on the Axin CBD but having different quadruplets of residues completely 
randomized (SI Fig. 3A). Three stringent selection cycles were performed, yielding 32 new 
sequences (SI Fig. 3B). Summarized in Fig. 3A are all the variants observed at least twice in the 
selected sequences. Taking into account the frequencies of amino acid substitution at various 
positions in the phage-derived Axin CBD variants, we synthesized 3 consensus peptides bearing a 
fluorescent label and measured their affinity for β-catenin using FP. All three of these sequences 
show improved binding to β-catenin, with the magnitude of the increase ranging from 8-39-fold (SI 
Fig. 3C and D). This information was then used in the design and evaluation of second-generation 7 
StAx peptides. Sequence inspection of the phage-optimized peptides (Fig. 3A) suggested that 
incorporation of a hydrophobic residue at position 468 and a Trp (or Phe) at positions 480 or 481 
gave rise to the boost in affinity for β-catenin, hence these changes were chosen for incorporation 
into second-generation stapled peptides (Fig. 3B). At the same time, we inspected the phage-derived 
peptides for patterns of residue utilization that were likely to promote or deter cell penetration. 
Though no hard-and-fast rules for cell-penetration have yet been derived, removal of negatively 
charged residues and introduction of Arg generally enhances cell penetration by stapled peptides 
(26), as it does for other cell-penetrating peptides (34). We noted that the sequences of the phage 
display-derived peptides suggested at least tolerability of a Glu to Arg substitution at position 467 
and Glu to Gln at position 470. These changes were therefore also incorporated into the second-
generation stapled peptides. 
Shown in Fig. 3B are sequences and β-catenin-binding affinities for stapled peptides bearing 
various sequence alterations grafted onto the StAx-3 framework. Truncation of the peptide to 
eliminate Glu467 and Gln468 (fStAx-31) had little effect on binding. Introduction of Glu470 to Gln 
and Gln478 to Arg mutations in fStAx-32 moderately reduced affinity for β-catenin. Replacement 
of Met481 with Trp improved binding affinity by a factor of 8 (fStAx-33). Another 2-fold increase 
in affinity was observed upon addition of Arg and Trp at positions 467 and 468 (fStAx-34), 
respectively. In order to increase the positive charge of the peptides, we further modified fStAx-34 
by addition of arginine residues yielding peptides fStAx-35 and -35R. Competition FP assays and 
surface plasmon resonance experiments show reversibility of StAx binding to β-catenin (SI Fig. 4). 
As negative controls, we designed and evaluated fStAx-40, -41 and -41R, which show decreasing 
affinity for β-catenin with an increasing number of modifications (Fig. 3B).  
Confocal fluorescence microscopy was used to evaluate cell-penetration by fStAx peptides (Fig. 
3C, SI Fig. 5). DLD1 colon cancer cells were incubated with 7.5 µM fluorescein-labeled fStAx 
peptides for 24 h followed by fixation and DAPI nuclear staining. Negatively and slightly positively 
charged peptides did not show significant cellular uptake (fStAx-31 to -33), whereas peptides with 
an overall charge of more than +2 (fStAx-34 to -41R) did efficiently penetrate cells. In particular, 
StAx-35 and -35R as well as the corresponding negative control peptides fStAx-41 and -41R 8 
showed high levels of intracellular fluorescence distributed throughout the cytosol and nucleus 
(green in Fig. 3C). 
The efficiency of the most highly cell-penetrant StAx peptides to compete with TCF4 for binding of 
β-catenin was investigated using an in vitro pull-down assay. Briefly, the glutathione-S-
transferase(GST)-tagged CBD of TCF4(1-52) was immobilized on glutathione-labeled agarose 
beads and used to precipitate β-catenin (Fig. 3D). In presence of N-terminally acetylated stapled 
peptides aStAx-35 and -35R, the binding of β-catenin to GST-TCF4(1-52) was inhibited 
competitively, but was unaffected by the presence of the negative control peptide aStAx-41R. To 
determine if the stapled peptides bind endogenous β-catenin, pull-down assays were performed in 
DLD1 cellular lysates. DLD1 is a Wnt-driven colon cancer cell line with elevated levels of β-
catenin. Biotinylated versions of stapled peptides bStAx-35, -40 and -41 were incubated with the 
lysate and subsequently treated with streptavidin conjugated beads to immobilize the peptides. For 
bStAx-35, western blot probing with β-catenin specific antibodies verified the formation of a 
bStAx-35/β-catenin complex (Fig. 3E). Treatment with control peptides bStAx40 and -41 resulted 
in only faint signals for β-catenin. 
Structural	 ﾠcharacterization	 ﾠof	 ﾠStAx-ﾭ‐35/β-ﾭ‐catenin	 ﾠinteraction	 ﾠ
To understand the molecular basis of the interaction between the StAx peptides and β-catenin we 
determined the crystal structure of N-terminally acetylated aStAx-35 in complex with residues 134-
665 of β-catenin at 3.0 Å resolution (Fig. 4, SI Table 2). A Fo-Fc difference map calculated using an 
unliganded β-catenin structure (PDB 1QZ7) (18) as a phasing model revealed unambiguously the 
presence of aStAx-35 in the structure and its binding site on β-catenin (Fig. 4A and B). The Cα 
superposition of residues 194-409 between β-catenin in the β-catenin/Axin and the β-
catenin/aStAx-35 structures (root mean square deviation = 0.47 Å) revealed a nearly identical 
overlay between the backbone of the wild-type Axin CBD peptide with the aStAx-35 stapled 
peptide (Cα root mean square deviation = 0.38 Å, see overlay in Fig. 4A). The wild-type residues of 
aStAx-35 interact with β-catenin in the same way as Axin itself, and the mutated residues appear to 
gain additional favorable interactions not made by the wild-type Axin CBD. In particular, the Trp 
residues at positions 468 and 481 that increased the binding affinity for β-catenin (Fig. 3B) appear 
to act as molecular “clasps” that bracket the ends of the peptide and engage recognition pockets of 9 
the surface of β-catenin (Fig. 4C and D). Trp481 forms an edge-to-face interaction with Trp338 of 
β-catenin (shortest C-C distance = 3.8 Å) and also appears to contribute a σ-hydrogen bond between 
the edge of Trp481 and the carboxyl oxygen of Asp299 in β-catenin (O-C distance = 3.0 Å). These 
two interactions between Trp481 of aStAx-35 and β-catenin are absent in the Axin peptide which 
has a methionine at position 481, and is presumably the origin of the 8-fold increase in affinity that 
accompanies this amino acid substitution. As mentioned above, arginines were added to aStAx-35 
at the N- and C-terminal positions 466 and 482, respectively as well as at positions 467 and 478 to 
increase cell permeability. The terminal amino acids Arg476 and Arg482 are disordered in the 
crystal structure, and Arg467 and Arg478 do not contact β-catenin. The hydrocarbon atoms of the 
staple, most of which are well-ordered (Fig. 4C and D), are oriented away from the interaction face 
of aStAx-35 and β-catenin and do not contribute directly to the protein/peptide interaction. 
Inhibition	 ﾠof	 ﾠβ-ﾭ‐catenin	 ﾠmediated	 ﾠtranscriptional	 ﾠactivities	 ﾠ
A reporter gene assay based on Wnt3a stimulation of HeLa cells was chosen to explore the effects 
of the StAx peptides on transcriptional activity. Cells were transfected with two constructs, one in 
which 10 tandem repeats of a TCF4 binding element with a minimum promoter was located 
upstream of the firefly luciferase cDNA (TOPflash), and the other construct containing a non-
inducible Renilla luciferase cDNA for normalization. In presence of the ligand Wnt3a, HeLa cells 
were treated with fStAx peptides for 24 hours followed by luciferase activity measurement. From 
the panel of peptides tested, fStAx-35 and -35R showed the most potent inhibition of β-
catenin/TCF4-driven firefly luciferase activity (Fig. 5A). At a concentration of 15 µM, fStAx-35 
and -35R were roughly three times more active in inhibiting luciferase activity than fStAx-34. 
Though StAx34 exhibits a higher affinity for β-catenin (Fig. 3B), the cellular uptake of this peptide 
is reduced in comparison to fStAx-35 and fStAx-35R (Fig. 3C). The luciferase activity of cells 
treated with active fStAx-35 and -35R shows dose-dependency whereas control peptide fStAx-41 
does not affect reporter activity (Fig. 5B).  
To validate the specificity of StAx peptides, we examined their activity in reporter assays having 
luciferase expression driven by promoter elements responsive to signaling pathways other than 
Wnt, namely Notch, Hedgehog, BMP and TGF-β. Whereas the Notch-driven reporter showed 
strong activation with NOTCH1 over-expression (Fig. 5C), which was diminished by treatment of 10 
the Notch pathway antagonist DAPT (35), no such diminution was seen upon corresponding 
treatment with 15 µM fStAx peptides. Similarly, fStAx peptides had no statistically significant 
effect on either basal or ligand-stimulated reporter gene transcription downstream of the Hedgehog, 
BMP or TGF-β signaling pathways (Fig. 5D). These data demonstrate that transcriptional 
antagonism by the StAx peptides is specific for the Wnt/β-catenin signaling pathway. 
Wnt pathway perturbants that act upstream of β-catenin can alter levels of the β-catenin protein. To 
determine whether StAx peptides modulate β-catenin levels, we employed western blotting with an 
anti-β-catenin antibody to examine total β-catenin protein levels, and also levels of the Axin1 
protein, in the presence and absence of StAx peptides (Fig. 5E). Consistent with previous reports 
(7-9), we observed stabilization of β-catenin in presence of LiCl, which is known to inhibit 
phosphorylation of β-catenin by GSK3β. Again as previously reported, treatment of cells with the 
small-molecule tankyrase inhibitor, XAV939, a known Axin-stabilizing agent (8), resulted in 
decreased β-catenin and elevated Axin levels. On the other hand, treatment with 10 µM aStAx 
peptides did not significantly alter total levels of either β-catenin or Axin, consistent with the StAx 
peptides acting by a mechanism downstream of the pathway components involved in regulating 
levels of both proteins. In addition, we investigated the ability of StAx peptides to interfere with β-
catenin/E-cadherin dimerization which is essential for cell integrity and independent of Wnt 
signaling. Pull-down experiments show that StAx-35R does not inhibit the binding of β-catenin to 
phosphorylated E-cadherin in vitro (SI Fig. 6B), which is in agreement with the reported high 
stability of this complex (2). The most likely mode of action for the StAx peptides entails direct 
interference of β-catenin binding to TCF transcription factors in the nucleus. 
Next we examined the effect of StAx peptides on mRNA expression levels of target genes 
previously shown to be transcriptionally upregulated by Wnt pathway activation. Two colorectal 
cancer cell lines known to have elevated β-catenin levels, DLD1 and SW480, were treated with 
StAx peptides for 24 hours followed by total RNA extraction and quantitative RT-PCR (qRT-PCR) 
of known β-catenin target genes LEF1, LGR5 and AXIN2 (1). In agreement with the findings of the 
TOPflash luciferase reporter assays described above, both fStAx-35 and -35R cause a substantial 
reduction in the mRNA levels of β-catenin/TCF target genes (Fig. 5F). 11 
Reduced	 ﾠviability	 ﾠof	 ﾠWnt-ﾭ‐dependent	 ﾠcancer	 ﾠcells	 ﾠ
Previous work has shown that inhibition of Wnt/β-catenin signaling can decrease the proliferation 
of Wnt-dependent cancer cell lines (7-9). We therefore tested the StAx peptides for their effects on 
the proliferation of cancer cells harboring genetic changes that result in dependence on β-catenin for 
growth and survival. The colorectal cancer cell lines DLD1 and SW480 harbor deletions of APC, 
whereas HCT116 harbors both APC deletion and a mutation in β-catenin that blocks ubiquitination; 
these lines were chosen on the basis of their known dependence on β-catenin for growth and 
survival. Treatment of DLD1 and SW480 cells with increasing concentrations (5 – 20 µM) of 
aStAx-35R caused a significant decrease in cellular ATP levels, as compared to DMSO and the 
negative control peptide aStAx-41R (Fig. 5G). Notably, time course experiments revealed efficient 
inhibition of cell proliferation after five days of treatment with 10 µM aStAx-35R (Fig. 5H). 
aStAx35-R has similar effects on the proliferation of DLD1 cells as does the tankyrase inhibitor 
XAV939 (SI Fig. 6C). Based on the selectivity of active StAx peptides for the inhibition of the Wnt 
signaling pathway, we expected the growth inhibitory effects of aStAx-35R to be selective for Wnt-
dependent cancer cells. In order to explore the selectivity of aStAx-35R, we compared its effect on 
Wnt-dependent cancer cell lines such as DLD1, SW480 and HCT116 with cell lines that are known 
to be independent of sustained Wnt signaling (RKO and A549) (7,8). After a five-day treatment 
with 10 µM aStAx-35R, we indeed observed selective inhibition of cellular proliferation ranging 
from 52 – 74% for the Wnt-dependent cell lines (Fig. 5I) whereas in RKO and A549 cancer cells 
proliferation was not affected (Fig. 5J). 
DISCUSSION	 ﾠ
An emerging theme in cancer biology is the inappropriate constitutive activation of signaling 
pathways that are ordinarily turned on during embryonic development but that subsequently 
become quiescent in most adult tissues. These pathways – Hedgehog, Notch, and Wnt, among 
others – have aroused great interest of late, because they appear to confer stem cell-like properties 
or “stemness” on cancers, and are associated with aggressive growth, propensity toward migration 
and invasiveness, and poor responsiveness to current treatments. Whereas agents that target the 
Hedgehog and Notch pathways are currently in clinical development, no such therapeutic option 12 
has emerged in the case of Wnt. The Wnt pathway was discovered by Nusse and Varmus for its 
association with virally induced mammary cancers in mice, but is now known to play a key role in 
establishment and maintenance of a wide range of cancers, the archetypal example being hereditary 
and spontaneous colon cancers. Oncogenic activation of Wnt signaling can ensue from a variety of 
primary molecular lesions, but nearly all share the common feature of increasing cellular levels of 
β-catenin by interfering with its constitutive degradation. β-Catenin serves as a signaling hub for the 
Wnt pathway, engaging in crucial protein-protein interactions with both negative and positive 
effectors of the Wnt pathway; the negative regulatory interactions with β-catenin are specifically 
disrupted in cancer, either through mutations in β-catenin or in its interacting partners. These 
findings have directed particular focus on β-catenin as the target of choice in Wnt-driven cancers, 
but attempts to discover selective high-affinity binders to β-catenin have not previously met with 
success. This is perhaps unsurprising in light of numerous X-ray structures of β-catenin bound to 
physiologic peptide ligands, which show extended binding interfaces some 60 Angstroms in length 
(as in Fig. 1B) and devoid of pronounced hydrophobic pockets conducive to the binding of small 
molecules (6-14). In the present work, we have employed the stapled peptide approach to obtain 
what to our knowledge are the first cell-permeable molecules rigorously shown to bind β-catenin 
directly and thereby block its ability to engage the transcriptional activator TCF4. 
Our initial studies focused on the CBD from the downstream target TCF4, but we found that this 
motif required not only the α-helical portion but also an extended appendage in order to bind with 
high affinity, and we were concerned that the latter would represent a proteolytic liability. We 
noticed however that a nearly all-helical CBD peptide from Axin bound to the same site as TCF4. 
Through a systematic approach that entailed screening of candidate stapling positions, affinity 
optimization via phage display, and introduction of residues that promote cell-penetration, we were 
able to discover stapled Axin-derived (StAx) peptides that function as direct β-catenin antagonists 
in vitro and in cultured cells. These peptides, but not closely related negative control molecules, 
interfere with transcriptional activation of canonical Wnt pathway genes, while leaving unaffected 
genes responsive to the Hedgehog, BMP and TGF-β cellular signaling pathways. The most active 
stapled peptide, aStAx-35R, was found to induce growth inhibition of Wnt-dependent cancer cells 
without affecting the growth of cancer cells that do not rely on deregulated Wnt signaling. 13 
Interestingly, though crystallographic analysis clearly demonstrates that StAx-35R binds at the 
same site as does Axin, the stapled peptide does not increase steady-state levels of β-catenin. This 
suggests that either the binding site for the stapled peptide is inaccessible in the cytoplasmic 
destruction complex, or that binding of the stapled peptide to that complex is insufficient to disrupt 
it. Whereas no changes were seen at the level of the β-catenin protein, strong suppression was 
observed at the mRNA level for a panel of canonical Wnt-driven genes but not for genes 
downstream of other signaling pathways. This transcriptional suppression indicates that aStAx-35R 
binding is sufficient to antagonize the nuclear form of β-catenin which is supported by in vitro 
competition experiments with the CBD of TCF4. Future efforts will aim to gain a more detailed 
understanding of the role of StAx peptides in this complex interaction network, to assess StAx 
peptides in animal models of Wnt-driven cancers, and to optimize the potency and pharmacologic 
properties of this new class of Wnt pathway-specific transcriptional antagonists. 
METHODS	 ﾠ
Peptide synthesis and characterization, phage display selection, cell-based assays, X-ray 
crystallography and structure determination were performed as described in SI Text. 
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